CytoDyn (CYDY) Liabilities and Shareholders Equity (2011 - 2026)

CytoDyn's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $18.5 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 12.71% year-over-year to $18.5 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $59.0 million (down 30.82% YoY) and the FY2025 annual result came in at $18.0 million, up 62.06% from the prior year.
• Liabilities and Shareholders Equity was $18.5 million for Q1 2026 at CytoDyn, up from $8.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $94.1 million in Q1 2022 and bottomed at $7.1 million in Q4 2022.
• A 5-year average of $21.2 million and a median of $14.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 93.18% — and 2024, when it jumped 169.23%.
• CytoDyn's Liabilities and Shareholders Equity stood at $7.1 million in 2022, then soared by 30.62% to $9.2 million in 2023, then jumped by 169.23% to $24.9 million in 2024, then slumped by 64.08% to $8.9 million in 2025, then jumped by 107.02% to $18.5 million in 2026.
• Business Quant data shows CYDY's Liabilities and Shareholders Equity at $18.5 million in Q1 2026, $8.9 million in Q4 2025, and $13.5 million in Q3 2025.